In this episode, 'Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD,' the panelists explore the practical integration of non-statin lipid-lowering therapies for high and very high-risk patients who remain above guideline-recommended LDL targets despite background statin therapy. The discussion opens with the importance of patient education around evolving LDL goals, noting that many patients were previously counseled to targets of less than 100 or less than 70 mg/dL and now need to understand why a more aggressive goal of less than 55 mg/dL, with an optimal range of 30 to 40 mg/dL, is being pursued. The panel emphasizes that since doubling a statin dose yields only an additional 5 to 6% LDL reduction, combination therapy is the necessary strategy for the vast majority of patients requiring further lowering. The conversation addresses the role of ezetimibe as an accessible first add-on, with PCSK9 inhibitors including monoclonal antibodies such as evolocumab and alirocumab, as well as inclisiran, reserved for patients who remain significantly above goal. The panelists also highlight the practical importance of precise clinical documentation, with one noting that clearly stating in the medical record that PCSK9 inhibitor initiation represents guideline-directed therapy is essential to navigating insurance and prior authorization barriers in the United States.

The discussion then turns to how specific comorbidities shape therapy selection, with the panel examining type 2 diabetes, chronic kidney disease, and established cardiovascular disease as conditions that can shift a patient from high to very high risk, thereby lowering the LDL goal and necessitating earlier combination therapy. For patients with type 2 diabetes, the panel notes a preference for directing more of the LDL lowering burden toward PCSK9 inhibitors rather than maximizing statin intensity, in order to avoid worsening glycemic control. The potential of early combination therapy in lipid-lowering naive patients presenting with myocardial infarction is also highlighted, with registry data suggesting superior outcomes compared to a stepwise escalation approach. The episode closes with a discussion of pioglitazone as an underutilized agent in type 2 diabetes that offers particular benefits for stroke prevention and cardiovascular risk reduction alongside its glucose-lowering properties, reinforcing the panel's broader message that comorbidities should be addressed directly with the therapies best suited to each condition while simultaneously pursuing the lowest achievable LDL goal.

The next episode in this series, 'Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD,' features the panelists advancing their conversation on ASCVD and focusing on the complex insurance and prior authorization landscape surrounding PCSK9 inhibitor access in the United States, while examining how shared decision-making, patient education, and strong prescriber-patient relationships drive long-term medication adherence in high-risk patients.